| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... Science translational medicine 12 (565), eabb0152, 2020 | 90 | 2020 |
| Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ... Science Translational Medicine 12 (565), eabb0391, 2020 | 64 | 2020 |
| Age-related differences in psychosocial function of children with craniofacial anomalies EJ Volpicelli, MJ Pfaff, K Hakimi, JP Bradley, RC Solem, JC Lee Plastic and Reconstructive Surgery 140 (4), 776-784, 2017 | 43 | 2017 |
| Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair “tetrafecta” Analysis (ROBUUST … A Veccia, U Carbonara, H Djaladat, R Mehazin, DD Eun, AC Reese, ... Journal of endourology 36 (6), 752-759, 2022 | 28 | 2022 |
| Disparities in telemedicine utilization for urology patients during the COVID-19 pandemic J Javier-DesLoges, M Meagher, S Soliman, J Yuan, K Hakimi, F Ghali, ... Urology 163, 76-80, 2022 | 19 | 2022 |
| Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database DN Patel, F Ghali, MF Meagher, J Javier-Desloges, SH Patel, S Soliman, ... Urologic Oncology: Seminars and Original Investigations 39 (1), 79. e1-79. e8, 2021 | 18 | 2021 |
| Outcomes of lymph node dissection in nephroureterectomy in the treatment of upper tract urothelial carcinoma: analysis of the ROBUUST registry K Hakimi, U Carbonara, H Djaladat, R Mehrazin, D Eun, A Reese, ... The Journal of urology 208 (2), 268-276, 2022 | 17 | 2022 |
| Partial versus radical nephrectomy for complex renal mass: multicenter comparative analysis of functional outcomes (Rosula collaborative group) C Cerrato, MF Meagher, R Autorino, G Simone, B Yang, RG Uzzo, ... Minerva Urology and Nephrology 75 (4), 425-433, 2023 | 7 | 2023 |
| Evaluation of insurance coverage and cancer stage at diagnosis among low-income adults with renal cell carcinoma after passage of the patient protection and affordable care act JF Javier-DesLoges, J Yuan, S Soliman, K Hakimi, MF Meagher, F Ghali, ... JAMA Network Open 4 (7), e2116267-e2116267, 2021 | 6 | 2021 |
| Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis C Saitta, JA Afari, R Autorino, U Capitanio, F Porpiglia, D Amparore, ... Urologic Oncology: Seminars and Original Investigations 41 (12), 487. e15 …, 2023 | 5 | 2023 |
| Impact of worsening surgically induced chronic kidney disease (CKD‐S) in preoperative CKD‐naïve patients on survival in renal cell carcinoma MV Nguyen, A Walia, A Saidian, D Puri, MF Meagher, K Hakimi, H Tanaka, ... BJU international 131 (2), 219-226, 2023 | 4 | 2023 |
| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020 A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... | 4 | 2020 |
| Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry C Saitta, JA Afari, A Walia, D Patil, H Tanaka, K Hakimi, L Wang, ... Urologic Oncology: Seminars and Original Investigations, 2024 | 2 | 2024 |
| Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy J Panian, A Saidian, K Hakimi, A Ajmera, WJ Anderson, P Barata, S Berg, ... The Oncologist, oyad166, 2023 | 2 | 2023 |
| Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial. K Hakimi, S Campbell, M Nguyen, N Rathi, L Wang, BI Rini, MC Ornstein, ... Journal of Clinical Oncology 41 (6_suppl), 683-683, 2023 | 2 | 2023 |
| Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC). J Panian, A Saidian, K Hakimi, A Ajmera, PC Barata, SA Berg, SL Chang, ... Journal of Clinical Oncology 40 (6_suppl), 334-334, 2022 | 2 | 2022 |
| Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients JF Javier-DesLoges, MF Meagher, A Walia, MV Nguyen, JM Perry, ... Urologic Oncology: Seminars and Original Investigations 39 (12), 837. e1-837. e7, 2021 | 2 | 2021 |
| PADRES (NCT03438708): Phase 2 Clinical Trial of Neoadjuvant Axitinib for Complex Partial Nephrectomy. K Hakimi, SC Campbell, MV Nguyen, N Rathi, L Wang, MF Meagher, ... BJU International, 2023 | 1 | 2023 |
| LBA01-08 INTERIM ANALYSIS OF PADRES (PRIOR AXITINIB AS A DETERMINANT OF OUTCOME OF RENAL SURGERY NCT03438708) CLINICAL TRIAL K Hakimi, S Campbell, M Nguyen, N Rathi, L Wang, B Rini, M Ornstein, ... The Journal of Urology 207 (Supplement 5), e1038, 2022 | 1 | 2022 |
| PD15-07 renal cell carcinoma paraneoplastic syndrome score: construction and validation S Soliman, S Noyes, M Meagher, J Rosenberg, A Leonard, K Hakimi, ... The Journal of Urology 207 (Supplement 5), e264, 2022 | 1 | 2022 |
